Breaking News: FDA Approves Perjeta for Early-Stage Breast Cancer
When: Wednesday, October 30, 2013
Noon - 1 p.m.
During our breaking news webinar, Hope S. Rugo, MD and Lisa K. Jablon, MD helped you
- learn about the recent FDA approval of pertuzumab (Perjeta) as a pre-surgery medicine for early-stage breast cancer, and what it means in the landscape of care
- understand health insurance coverage of the medicine and its cost
- discover its possible side effects and the ways your healthcare team will work together to determine if this medicine is right for you
About Our Speakers
Hope S. Rugo, MD is a professor of medicine in the division of hematology and oncology at the University of California San Francisco (UCSF) Carol Franc Buck Breast Cancer Center, where she co-directs the Breast Oncology Clinical Trials Program. Her research interests include new, innovative therapies for women with advanced breast cancer; evaluation of special circulating cells to help understand response to therapy; complementary medicine and supportive care.
Dr. Rugo is a member of the Breast Core Committee of the Alliance for Clinical Trials in Oncology network, where she is the principal investigator of CALGB 40502, a now fully accrued phase III trial comparing novel chemotherapy agents in the treatment of advanced breast cancer. She is also an investigator of SPORE (Specialized Program of Research Excellence in Breast Cancer) in the Bay Area and an investigator and novel agent chaperone for ISPY2, an innovative multicenter neoadjuvant chemotherapy trial. Dr. Rugo has published many peer-reviewed papers, given presentations on a variety of cancer-related topics, and is the breast section editor of Cancer.Net, a patient-focused publication of the American Society of Clinical Oncology.
Lisa K. Jablon, MD is a breast surgeon and the director of the breast health program, a nationally recognized breast center accredited by the American College of Surgeons, at the Albert Einstein Medical Center. Dr. Jablon practices the latest surgical technique such as skin sparing mastectomy and sentinel node biopsies.
Dr. Jablon is also the director of the genetics risk program at Albert Einstein. The program helps counsel women about their family history of breast and ovarian cancer, assess their risk, and develop a plan to implement prevention options and monitor health. She is a member of LBBC’s Medical Advisory Board and frequently speaks for us and reviews our publications.